US Bancorp DE Acquires 790 Shares of Biohaven Ltd. (NYSE:BHVN)

US Bancorp DE increased its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 57.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,173 shares of the company’s stock after buying an additional 790 shares during the period. US Bancorp DE’s holdings in Biohaven were worth $109,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in BHVN. Vanguard Group Inc. increased its stake in shares of Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company’s stock worth $345,031,000 after purchasing an additional 4,650,702 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Biohaven by 6.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,347,022 shares of the company’s stock worth $183,050,000 after buying an additional 212,699 shares during the last quarter. Farallon Capital Management LLC raised its stake in shares of Biohaven by 181.4% in the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock valued at $78,028,000 after buying an additional 1,449,000 shares during the period. Darwin Global Management Ltd. purchased a new position in shares of Biohaven during the 1st quarter valued at $80,776,000. Finally, Armistice Capital LLC grew its stake in shares of Biohaven by 74.8% during the 2nd quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after acquiring an additional 597,705 shares during the period. Institutional investors own 88.78% of the company’s stock.

Insider Buying and Selling

In other news, Director Gregory Bailey bought 5,000 shares of the stock in a transaction on Tuesday, September 24th. The stock was bought at an average cost of $44.19 per share, for a total transaction of $220,950.00. Following the completion of the purchase, the director now directly owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. The trade was a 0.31 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director John W. Childs bought 21,052 shares of Biohaven stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the transaction, the director now directly owns 21,052 shares in the company, valued at $999,970. This represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.00% of the stock is currently owned by insiders.

Biohaven Stock Performance

BHVN stock opened at $44.39 on Friday. The firm has a fifty day moving average price of $48.16 and a 200 day moving average price of $40.92. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The firm has a market cap of $4.49 billion, a PE ratio of -4.75 and a beta of 1.31.

Biohaven (NYSE:BHVN) last released its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, equities analysts predict that Biohaven Ltd. will post -8.81 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BHVN shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Biohaven in a research note on Wednesday, October 23rd. UBS Group dropped their target price on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Leerink Partners lifted their price target on Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Piper Sandler raised their target price on Biohaven from $66.00 to $76.00 and gave the stock an “overweight” rating in a research note on Monday, September 23rd. Finally, Robert W. Baird upped their price target on Biohaven from $58.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Thirteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $63.42.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.